AdAlta and Cell Therapies partnership announcement

AdAlta Limited (ASX: $1AD) has partnered with Cell Therapies Pty Ltd (CTPL) to establish CTPL as its preferred manufacturer of cellular immunotherapies. The Master Services Agreement (MSA) between the two companies aims to provide AdCella, AdAlta's cellular immunotherapy collaboration with SYNthesis BioVentures (SYNBV), with access to key product development, manufacturing, and supply chain capabilities.

CTPL CEO and AdAlta CEO statements

CTPL Chief Executive Officer, Dr Bev Menner, expressed the company's pleasure in partnering with AdAlta and AdCella to bring cellular immunotherapy innovation from Asia to Australian and global patients. AdAlta CEO and Managing Director, Dr Tim Oldham, highlighted the collaboration with CTPL as a crucial step in their strategy to bring innovative cellular immunotherapies into a western regulated environment.

AdAlta and Cell Therapies partnership summary

AdAlta Limited (ASX: $1AD) has executed a Master Services Agreement (MSA) with Cell Therapies Pty Ltd (CTPL) to establish CTPL as its preferred manufacturer of cellular immunotherapies. This partnership aims to bring innovative cellular immunotherapies originating in Asia to patients worldwide, leveraging AdAlta's i-body® technology and a pathway to western regulated markets. The MSA provides access to CTPL's expertise in development and manufacturing of cellular immunotherapies and state-of-the-art facilities. Initial work under the MSA is anticipated to focus on Technical Feasibility Assessments of AdCella's in-licensing candidates, with an outlook to transfer manufacturing processes into CTPL facilities and manufacture patient doses for Phase I clinical trials. The partnership signifies a significant step towards AdAlta's goal of delivering innovative cellular immunotherapies to a global patient base.